Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2025-04-15 Delisting Announcement
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Proposed cancellation of trading on AIM
Delisting Announcement Classification · 1% confidence The document is an official announcement from MaxCyte, Inc. regarding the proposed cancellation of its listing on the AIM market (delisting). It details the reasons for the delisting, the expected timeline, and the requirement for shareholder approval at an upcoming annual meeting. While it mentions that a proxy statement will be filed later, the document itself is a formal regulatory announcement of a corporate action (delisting). According to the provided definitions, a 'Delisting Announcement' (DLST) is the most specific and accurate classification for this content.
2025-04-15 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by BlackRock, Inc. regarding its shareholding in MaxCyte, Inc. This is a regulatory requirement for institutional investors to disclose when their voting rights cross specific thresholds. Based on the provided filing categories, this document fits the definition of a 'Major Shareholding Notification' (Code: MRQ).
2025-04-14 English
MaxCyte to Report Q1 2025 Results on May 7, 2025
Report Publication Announcement Classification · 1% confidence The document is an announcement from MaxCyte, Inc. regarding the upcoming release of their first quarter 2025 financial results and the scheduling of a conference call. It does not contain the actual financial results, but rather serves as a notification of when those results will be published. Following the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2025-04-10 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by BlackRock, Inc. regarding their shareholding in MaxCyte, Inc. This is a regulatory requirement for disclosing significant changes in share ownership (crossing thresholds). According to the provided filing definitions, this falls under 'Major Shareholding Notification'.
2025-04-08 English
Total Voting Rights
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement from MaxCyte, Inc. regarding the issuance of new common stock following the exercise of share options and the vesting of restricted stock units. It explicitly states the new total voting rights and issued share capital. This falls under the category of share capital changes and new share issues, which is classified as SHA.
2025-04-01 English
Correction: Vesting of RSUs and PDMR Dealing
Director's Dealing Classification · 1% confidence The document is an official regulatory announcement identified by the 'RNS Number' and the reference to the 'UK Market Abuse Regulation'. The content explicitly details transactions (vesting of RSUs and subsequent sale to cover tax) conducted by a Person Discharging Managerial Responsibilities (PDMR), Douglas Swirsky, Chief Financial Officer. This type of insider transaction reporting, especially when filed with the SEC and disseminated via RNS, falls under the category of Director's Dealing or insider trading disclosure. The specific code for this is 'DIRS'. Although it is disseminated via RNS, the core content is a Director's Dealing report, making DIRS the most specific classification.
2025-03-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.